About the Company
PixarBio will lead the Non-Opiate Revolution around Non-Addictive Pain treatments.
NeuroRelease FDA approval is expected in 2018, mitigates sensory (pain) signaling without effecting locomotion (moving) signals and we have the potential to replace morphine in the clinic.
- To defeat Rebound Pain over 40 surgical procedures require 14 days of post-op pain treatment
- 100% of surgeons prefer non addictive pain treatments over morphine
- Over 90% of patients prefer non-addictive post op pain treatment over morphine
NeuroRelease is expected to receive FDA approval for post-op pain in 2018, and with our growing team of industry experts NeuroRelease will create a new clinical franchise in medicine around NeuroRelease’s pain product pipeline.
More importantly, we’ll change the way medicine is delivered throughout the world.
Lead pain treatments will last up to 14 days, 7 days, 90 days, for the clinic and 4-8 hours for dentistry.
PixarBio Corporation to Attend and Discuss NeuroRelease™ a Morphine Replacement, Non-Opiate, Non Addictive Pain Treatment at the 2017 BIO CEO & Investor Conference in NYC, NY, February 13-14, 2017
CAMBRIDGE, Mass.–(BUSINESS WIRE)— PixarBio Corporation (PXRB) developers of NeuroReleaseTM, a morphine replacement, non-opiate/opioid, non-addictive pain treatment with FDA approval expected in late 2018 for our 14-day post-surgical pain treatment, announced today that it will be attending the BIO CEO...
CAMBRIDGE, Mass.–(BUSINESS WIRE)— PixarBio Corporation, (PXRB) today announced that we will stay focused on our NeuroRelease Pain platform and continue to drive our non-opiate non addictive morphine replacement to market with FDA approval expected between the end of 2018...
NEW YORK, NY / ACCESSWIRE / December 19, 2016 / SeeThruEquity, the leading independent equity research firm focused on smallcap and microcap public companies, today announced it has issued an update note on PixarBio Corporation (PXRB). The report is...
PixarBio Corporation CEO Frank Reynolds to Present NeuroRelease™ a Morphine Replacement, Non-Opiate, Non Addictive Pain Treatment at the 2017 Biotech Showcase in San Francisco, CA on Tuesday, January 10th at 10am PST
CAMBRIDGE, Mass.–(BUSINESS WIRE)— PixarBio Corporation, (PXRB) developers of NeuroRelease™, a morphine replacement, non-opiate/opioid, non-addictive pain treatment with FDA approval expected in early 2019, announced today that its Chief Executive Officer and Chief Science Officer Frank Reynolds will present at...